NL
Nicole LaBrosse (SVP, CHIEF FINANCIAL OFFICER) filed 2 Form 4 reports in the past 24 months (0 purchases, 2 sales), most often in Halozyme Therapeutics, Inc. (HALO). The largest single filing was $1.5M of HALO (20,000 sh across 2 lots, as filed), executed Sep 10 2025. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
2
0 buys · 2 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$1.7M
shares × price, as filed
Last traded
Sep 22 2025
Filed Sep 23 2025
Median ADV $214.5M across their filed names
Open performance→Volume by month
Buys $0
Sells $1.7M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 24 months
Most traded names
HALORecent filings
HALOSALE
Halozyme Therapeutics, Inc.
View filing →
$149K1,913 sh × $77.83
Exec Sep 22 2025
Filed Sep 23 2025 · 5:30 PM ET HALOSALE Halozyme Therapeutics, Inc. View filing → $1.5M
20,000 sh across 2 lots
Exec Sep 10 2025
Filed Sep 11 2025 · 5:30 PM ET